NCM · Medical - Care Facilities
Starling Oncology, Inc. (STLN) Stock
$6.63
+7.28%
NCM: STLN
Healthcare
Valuation
Financials & Margins
Annual Financials (USD)
Balance Sheet (USD)
Latest News
Oncology Institute Q2 Earnings Call Highlights
MarketBeat · Aug 7, 2026
The Oncology Institute, Inc. (STLN) Reports Q2 Loss, Tops Revenue Estimates
Zacks · Aug 6, 2026
Starling Oncology Reports Second Quarter 2026 Financial Results and Updates Full-Year 2026 Guidance
GlobeNewswire · Aug 6, 2026
Earnings To Watch: Starling Oncology Inc (STLN) Q2 2026 -- GF Value Sees 44% Downside
GuruFocus.com · Aug 5, 2026
The Oncology Institute Changes Name to Starling Oncology
MT Newswires · Aug 3, 2026
Cash Flow (USD)
Valuation & Return Ratios
Ownership
Insiders Held18.07%
Institutions Held46.46%
Institutions Float Held56.70%
Peer Comparison
About Starling Oncology, Inc.
Starling Oncology, Inc. is headquartered in US.
Starling Oncology, Inc. (STLN) stock trades at $6.63 with a market capitalization of $662.89M. The stock is valued at a price-to-earnings (P/E) ratio of -20.83, price-to-book of -25.85, price-to-sales of 1.06. Over the past 52 weeks the stock has ranged between $2.32 and $7.13, and currently trades 7.0% below its 52-week high.
On profitability, Starling Oncology, Inc. generates a return on equity (ROE) of 209.81% — well above the market average, a sign of a high-quality business, return on capital employed of -31.32%, an operating margin of -7.16%, a net profit margin of -6.18%.